These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3258 related items for PubMed ID: 15663992

  • 1. Endocrine treatment of prostate cancer.
    Tammela T.
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [Abstract] [Full Text] [Related]

  • 2. Endocrine prevention and treatment of prostate cancer.
    Tammela TL.
    Mol Cell Endocrinol; 2012 Sep 05; 360(1-2):59-67. PubMed ID: 22465099
    [Abstract] [Full Text] [Related]

  • 3. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
    Tsukamoto S, Akaza H.
    Gan To Kagaku Ryoho; 2001 Jul 05; 28(7):917-26. PubMed ID: 11478140
    [Abstract] [Full Text] [Related]

  • 4. Endocrine therapy for prostate cancer.
    Damber JE.
    Acta Oncol; 2005 Jul 05; 44(6):605-9. PubMed ID: 16165920
    [Abstract] [Full Text] [Related]

  • 5. Combined androgen blockade: the gold standard for metastatic prostate cancer.
    McLeod DG, Crawford ED, DeAntoni EP.
    Eur Urol; 1997 Jul 05; 32 Suppl 3():70-7. PubMed ID: 9267789
    [Abstract] [Full Text] [Related]

  • 6. [First line therapy in the treatment of metastatic prostate cancer].
    Sakai H, Kanetake H.
    Gan To Kagaku Ryoho; 2003 Jan 05; 30(1):43-9. PubMed ID: 12557704
    [Abstract] [Full Text] [Related]

  • 7. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR, CaPSURE Investigators.
    Cancer; 2006 Apr 15; 106(8):1708-14. PubMed ID: 16544313
    [Abstract] [Full Text] [Related]

  • 8. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
    Moreau JP, Delavault P, Blumberg J.
    Clin Ther; 2006 Oct 15; 28(10):1485-508. PubMed ID: 17157109
    [Abstract] [Full Text] [Related]

  • 9. [Keyrole of endocrinology in the victory against prostate cancer].
    Labrie F.
    Bull Cancer; 2006 Sep 15; 93(9):949-58. PubMed ID: 16980238
    [Abstract] [Full Text] [Related]

  • 10. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
    Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A.
    Actas Urol Esp; 2011 Sep 15; 35(10):565-79. PubMed ID: 21757258
    [Abstract] [Full Text] [Related]

  • 11. [Hormone therapy for prostate cancer].
    Théodore C.
    Bull Cancer; 2004 Jan 15; 91(1):69-74. PubMed ID: 14975807
    [Abstract] [Full Text] [Related]

  • 12. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y, Akaza H, Okada K, Yokoyama M, Moriyama N, Usami M, Hirao Y, Tsushima T, Sakamoto A, Ohashi Y, Aso Y, Prostate Cancer Study Group.
    Int J Urol; 2004 May 15; 11(5):295-303. PubMed ID: 15147545
    [Abstract] [Full Text] [Related]

  • 13. Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP.
    Hinotsu S, Akaza H, Usami M, Ogawa O, Kagawa S, Kitamura T, Tsukamoto T, Naito S, Namiki M, Hirao Y, Murai M, Yamanaka H, Japan Study Group of Prostate Cancer (J-CaP).
    Jpn J Clin Oncol; 2007 Oct 15; 37(10):775-81. PubMed ID: 17965423
    [Abstract] [Full Text] [Related]

  • 14. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.
    J Urol; 2008 Sep 15; 180(3):921-7. PubMed ID: 18635218
    [Abstract] [Full Text] [Related]

  • 15. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
    Scherr DS, Pitts WR.
    J Urol; 2003 Nov 15; 170(5):1703-8. PubMed ID: 14532759
    [Abstract] [Full Text] [Related]

  • 16. Monotherapy in advanced prostate cancer: an overview.
    Baltogiannis D, Giannakopoulos X, Charalabopoulos K, Sofikitis N.
    Exp Oncol; 2004 Sep 15; 26(3):185-91. PubMed ID: 15494685
    [Abstract] [Full Text] [Related]

  • 17. Current treatment of advanced prostate cancer.
    Ismail M, Gomella LG.
    Tech Urol; 1997 Sep 15; 3(1):16-24. PubMed ID: 9170220
    [Abstract] [Full Text] [Related]

  • 18. [Hormone therapy of locally advanced and metastatic prostate carcinoma].
    Rübben H.
    Praxis (Bern 1994); 2001 Sep 20; 90(38):1641-4. PubMed ID: 11675917
    [Abstract] [Full Text] [Related]

  • 19. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K, Lehnert M, Stettner H, Hubmer G.
    Eur Urol; 1997 Sep 20; 32 Suppl 3():81-5. PubMed ID: 9267791
    [Abstract] [Full Text] [Related]

  • 20. [New development of endocrine therapy in prostate cancer].
    Naito S.
    Gan To Kagaku Ryoho; 1996 May 20; 23(6):684-8. PubMed ID: 8645018
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 163.